DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: COREG CR (Drug); Lisinopril (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, MD, Study Director, Affiliation: GlaxoSmithKline


This study will be a randomized study investigating the bioequivalence of COREG CR to its components, COREG and Lisinopril (ZESTRIL). PK samples will be obtained throughout the study to investigate the PK of COREG CR FDC to COREG and Lisinopril

Clinical Details

Official title: A Randomized, Open-label, Single-dose, Crossover Study to Demonstrate the Bioequivalence of the Final Fixed Dose Combination (FDC) Formulation (COREG CR & Lisinopril) to COREG CR & ZESTRIL Employed in the Phase III Factorial Study

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome: To establish bioequivalence of the final FDC product (80 mg carvedilol CR/10 mg lisinopril) relative to concomitant dosing of COREG CR (80 mg) and ZESTRIL (10 mg, over encapsulated)throughout the study

Secondary outcome:

To further evaluate the pharmacokinetic profile of the final FDC product. To evaluate the safety and tolerability of single doses of the fixed dose combination at the highest dose strengths of each component throughout the study

plasma levels of carvedilol to determine pharmacokinetic parameters.

plasma levels of lisinopril determine pharmacokinetic parameters.


Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.


Inclusion Criteria:

- Adult males and females of non-child bearing potential who are between 18 to 55 years

of age, inclusively

- Body weight > 60 kg (132 lbs) and body mass index (BMI) between 19 and 33

Exclusion criteria:

- Any clinically relevant abnormality identified on the screening history, physical or

laboratory examination, or any other medical condition or circumstance making the volunteer unsuitable for participation in the study.

- Subjects who metabolize carvedilol poorly based on CYP2D6 genotyping as determined at


- Treatment with any prescription or non-prescription drugs (including vitamins, herbal

and dietary supplements, as well as grapefruit-containing products) within 7 days or 5 half-lives prior to first dose of study medication and until the end of the study. Treatment with any prescription drugs that are CYP2D6 inhibitors within 14 days prior to the first dose of study medication until the end of the study. Excluded from this list is acetaminophen at doses of ≤ 2 grams/day.

- Treatment with an investigational drug within 30 days or 5 half-lives (whichever is

longer) preceding Day 1 of Session 1.

- Exposure to more than four new chemical entities within 12 months prior to the first

dosing day.

- History of regular alcohol consumption exceeding 7 drinks/week for women or 14

drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1. 5 ounces of hard liquor) within 6 months of screening.

- Positive urine drug screen (UDS) including alcohol at screening. A minimum list of

drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.

- Urine Na/creatinine ratio < 0. 1 meq/mg.

- Positive for Hepatitis B surface antigen or HIV.

- Women of child-bearing potential.

- Resting heart rate of ≤ 50 beats per minute (bpm) at screening.

- Any abnormalities as defined in the protocol on 12-lead ECG during screening

- Documented history of low blood pressure (average SBP ≤ 110 mm Hg and/or DBP ≤50 mm

Hg) or blood pressure below these values at time of screening.

- Orthostatic hypotension diagnosed at screening (orthostatic hypotension will be

defined as a reduction in systolic blood pressure of 20 mmHg or more and/or a reduction in diastolic blood pressure of 10 mmHg or more for standing vs. supine measurements.

- Donation of blood in excess of 500 mL within a 56 day period, including ~478 mL of

blood drawn during this study.

- History of asthma, COPD and/or hypersensitivity to β-adrenergic blocking agents.

- History of sensitivity to heparin, heparin- induced thrombocytopenia, or sensitivity

to any of the study medications or components thereof.

- History of anaphylaxis or anaphylactoid reactions or severe allergic responses to


- History of angioedema.

- Unwillingness or inability to follow the procedures outlined in the protocol or

inability to provide written informed consent.

- History of sensitivity to carvedilol, lisinopril, alpha-blockers, beta-blockers or

ACE inhibitors.

Locations and Contacts

GSK Investigational Site, Tacoma, Washington 98418, United States
Additional Information

Starting date: September 2007
Last updated: October 13, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017